-
公开(公告)号：US20080317778A1
公开(公告)日：2008-12-25
申请号：US12200176
申请日：2008-08-28
申请人： Paul Chaplin , Paul Howley , Christine Meisinger-Henschel , Ingmar Rathe , Eva Felder , Karl Heller
发明人： Paul Chaplin , Paul Howley , Christine Meisinger-Henschel , Ingmar Rathe , Eva Felder , Karl Heller
CPC分类号： A61K39/285 , A61K39/12 , A61K48/00 , A61K2039/5254 , A61K2039/5256 , A61K2039/53 , A61K2039/545 , C07K14/005 , C12N7/00 , C12N15/86 , C12N2710/24134 , C12N2710/24143 , C12N2710/24151 , C12N2740/16322
摘要： The present invention provides an attenuated virus, which is derived from Modified Vaccinia Ankara virus and characterized by the loss of its capability to reproductively replicate in human cell lines. It further describes recombinant viruses derived from this virus and the use of the virus, or its recombinants, as a medicament or vaccine. A method is provided for inducing an immune response in individuals who may be immune-compromised, receiving antiviral therapy, or have a pre-existing immunity to the vaccine virus. In addition, a method is provided for the administration of a therapeutically effective amount of the virus, or its recombinants, in a vaccinia virus prime/vaccinia virus boost inoculation regimen. The present invention relates to a method of virus amplification in primary cells which are cultivated in a serum free medium. Viruses produced by this method are advantageously free of any infectious agents comprised in animal sera.
摘要翻译： 本发明提供一种减毒病毒，其衍生自改良的痘苗安卡拉病毒，其特征在于丧失其在人细胞系中繁殖复制的能力。 它还描述了源自该病毒的重组病毒和病毒或其重组体作为药物或疫苗的用途。 提供了一种方法，用于在可能被免疫损害的个体中诱导免疫应答，接受抗病毒治疗或具有疫苗病毒的预先存在的免疫。 此外，提供了一种用于在痘苗病毒原/痘苗病毒加强接种方案中施用治疗有效量的病毒或其重组体的方法。 本发明涉及在无血清培养基中培养的原代细胞中的病毒扩增方法。 通过该方法产生的病毒有利地不含动物血清中包含的任何传染性物质。
-
公开(公告)号：US07459270B2
公开(公告)日：2008-12-02
申请号：US11999127
申请日：2007-12-04
IPC分类号： C12Q1/70 , C12N5/10 , C12N15/863 , A61K39/275 , A61K39/285 , A61K48/00
CPC分类号： C07K14/005 , A61K39/12 , A61K39/285 , A61K48/00 , A61K2039/5254 , A61K2039/5256 , A61K2039/53 , A61K2039/545 , C12N7/00 , C12N15/86 , C12N2710/24121 , C12N2710/24143 , C12N2740/16322
摘要： The present invention provides an attenuated virus, which is derived from Modified Vaccinia Ankara virus and characterized by the loss of its capability to reproductively replicate in human cell lines. It further describes recombinant viruses derived from this virus and the use of the virus, or its recombinants, as a medicament or vaccine. A method is provided for inducing an immune response in individuals who may be immune-compromised. In addition, a method is provided for the administration of a therapeutically effective amount of the virus, or its recombinants, in a vaccinia virus prime/vaccinia virus boost inoculation regimen.
-
公开(公告)号：US07384644B2
公开(公告)日：2008-06-10
申请号：US11198557
申请日：2005-08-05
IPC分类号： A61K39/00 , A61K39/275 , C12N7/08 , A61K39/23
CPC分类号： C07K14/005 , A61K39/12 , A61K39/285 , A61K48/00 , A61K2039/5254 , A61K2039/5256 , A61K2039/53 , A61K2039/545 , C12N7/00 , C12N15/86 , C12N2710/24121 , C12N2710/24143 , C12N2740/16322
摘要： The present invention provides an attenuated virus, which is derived from Modified Vaccinia Ankara virus and characterized by induction of protective immunity against a lethal vaccinia virus infection in a mouse, whereby the effective amount of the MVA-BN virus, or a derivative thereof, required to confer said immunity is less than the effective amount of MVA-575 required to render said mouse immune to a lethal vaccinia virus infection, and/or the MVA-BN virus, or a derivative thereof, induces at least substantially the same level of immunity in vaccinia virus prime/vaccina virus boost regimes when compared to DNA prime/vaccinia virus boost regimes. It further describes recombinant viruses derived from this virus and the use of the virus, or its recombinants, as a medicament or vaccine. A method is provided for inducing an immune response in individuals who may be immune-compromised, receiving antiviral therapy, or have a pre-existing immunity to the vaccine virus.
摘要翻译： 本发明提供一种减毒病毒，其来源于改良牛痘安卡拉病毒，其特征在于在小鼠中诱导针对致死性痘苗病毒感染的保护性免疫力，由此需要有效量的MVA-BN病毒或其衍生物 赋予所述免疫力小于使所述小鼠免疫致死性痘苗病毒感染所需的MVA-575的有效量，和/或MVA-BN病毒或其衍生物诱导至少基本上相同的免疫水平 与DNA痘苗/痘苗病毒增强方案相比，在痘苗病毒原始/疫苗病毒增强方案中。 它还描述了源自该病毒的重组病毒和病毒或其重组体作为药物或疫苗的用途。 提供了一种方法，用于在可能被免疫损害的个体中诱导免疫应答，接受抗病毒治疗或具有疫苗病毒的预先存在的免疫。
-
公开(公告)号：US08268325B2
公开(公告)日：2012-09-18
申请号：US13053361
申请日：2011-03-22
IPC分类号： A61K39/12
CPC分类号： C07K14/005 , A61K39/12 , A61K39/285 , A61K48/00 , A61K2039/5254 , A61K2039/5256 , A61K2039/53 , A61K2039/545 , C12N7/00 , C12N15/86 , C12N2710/24121 , C12N2710/24143 , C12N2740/16322
摘要： The present invention provides an attenuated virus, which is derived from Modified Vaccinia Ankara virus, wherein the MVA-BN virus, or a derivative thereof, induces at least substantially the same level of immunity in vaccinia virus prime/vaccina virus boost regimes when compared to DNA prime/vaccinia virus boost regimes. It further describes recombinant viruses derived from this virus and the use of the virus, or its recombinants, as a medicament or vaccine. A method is provided for inducing an immune response in individuals who may be immune-compromised, receiving antiviral therapy, or have a pre-existing immunity to the vaccine virus.
摘要翻译： 本发明提供了一种减毒病毒，其来源于改良的痘苗病毒安卡拉病毒，其中MVA-BN病毒或其衍生物在痘苗病毒原/疫苗病毒增强方案中诱导至少基本相同的免疫水平， DNA原核/痘苗病毒增强体系。 它还描述了源自该病毒的重组病毒和病毒或其重组体作为药物或疫苗的用途。 提供了一种方法，用于在可能被免疫损害的个体中诱导免疫应答，接受抗病毒治疗或具有疫苗病毒的预先存在的免疫。
-
公开(公告)号：US08236560B2
公开(公告)日：2012-08-07
申请号：US13106176
申请日：2011-05-12
申请人： Paul Chaplin , Paul Howley , Christine Meisinger-Henschel , Ingmar Rathe , Eva Felder , Karl Heller
发明人： Paul Chaplin , Paul Howley , Christine Meisinger-Henschel , Ingmar Rathe , Eva Felder , Karl Heller
IPC分类号： A01N63/00
CPC分类号： A61K39/285 , A61K39/12 , A61K48/00 , A61K2039/5254 , A61K2039/5256 , A61K2039/53 , A61K2039/545 , C07K14/005 , C12N7/00 , C12N15/86 , C12N2710/24134 , C12N2710/24143 , C12N2710/24151 , C12N2740/16322
摘要： The present invention provides an attenuated virus, which is derived from Modified Vaccinia Ankara virus and characterized by the loss of its capability to reproductively replicate in human cell lines. It further describes recombinant viruses derived from this virus and the use of the virus, or its recombinants, as a medicament or vaccine. A method is provided for inducing an immune response in individuals who may be immune-compromised, receiving antiviral therapy, or have a pre-existing immunity to the vaccine virus. In addition, a method is provided for the administration of a therapeutically effective amount of the virus, or its recombinants, in a vaccinia virus prime/vaccinia virus boost inoculation regimen. The present invention relates to a method of virus amplification in primary cells which are cultivated in a serum free medium. Viruses produced by this method are advantageously free of any infectious agents comprised in animal sera.
摘要翻译： 本发明提供一种减毒病毒，其衍生自改良的痘苗安卡拉病毒，其特征在于丧失其在人细胞系中繁殖复制的能力。 它还描述了源自该病毒的重组病毒和病毒或其重组体作为药物或疫苗的用途。 提供了一种方法，用于在可能被免疫损害的个体中诱导免疫应答，接受抗病毒治疗或具有疫苗病毒的预先存在的免疫。 此外，提供了一种用于在痘苗病毒原/痘苗病毒加强接种方案中施用治疗有效量的病毒或其重组体的方法。 本发明涉及在无血清培养基中培养的原代细胞中的病毒扩增方法。 通过该方法产生的病毒有利地不含动物血清中包含的任何传染性物质。
-
公开(公告)号：US07923017B2
公开(公告)日：2011-04-12
申请号：US11977808
申请日：2007-10-26
CPC分类号： C07K14/005 , A61K39/12 , A61K39/285 , A61K48/00 , A61K2039/5254 , A61K2039/5256 , A61K2039/53 , A61K2039/545 , C12N7/00 , C12N15/86 , C12N2710/24121 , C12N2710/24143 , C12N2740/16322
摘要： The present invention provides an attenuated virus, which is derived from Modified Vaccinia Ankara virus, wherein the MVA-BN virus, or a derivative thereof, induces at least substantially the same level of immunity in vaccinia virus prime/vaccina virus boost regimes when compared to DNA prime/vaccinia virus boost regimes. It further describes recombinant viruses derived from this virus and the use of the virus, or its recombinants, as a medicament or vaccine. A method is provided for inducing an immune response in individuals who may be immune-compromised, receiving antiviral therapy, or have a pre-existing immunity to the vaccine virus.
摘要翻译： 本发明提供了一种减毒病毒，其来源于改良的痘苗病毒安卡拉病毒，其中MVA-BN病毒或其衍生物在痘苗病毒原/疫苗病毒增强方案中诱导至少基本相同的免疫水平， DNA原核/痘苗病毒增强体系。 它还描述了源自该病毒的重组病毒和病毒或其重组体作为药物或疫苗的用途。 提供了一种方法，用于在可能被免疫损害的个体中诱导免疫应答，接受抗病毒治疗或具有疫苗病毒的预先存在的免疫。
-
公开(公告)号：US08470598B2
公开(公告)日：2013-06-25
申请号：US13544201
申请日：2012-07-09
申请人： Paul Chaplin , Paul Howley , Christine Meisinger-Henschel , Ingmar Rathe , Eva Felder , Karl Heller
发明人： Paul Chaplin , Paul Howley , Christine Meisinger-Henschel , Ingmar Rathe , Eva Felder , Karl Heller
IPC分类号： A01N63/00
CPC分类号： A61K39/285 , A61K39/12 , A61K48/00 , A61K2039/5254 , A61K2039/5256 , A61K2039/53 , A61K2039/545 , C07K14/005 , C12N7/00 , C12N15/86 , C12N2710/24134 , C12N2710/24143 , C12N2710/24151 , C12N2740/16322
摘要： The present invention provides an attenuated virus, which is derived from Modified Vaccinia Ankara virus and characterized by the loss of its capability to reproductively replicate in human cell lines. It further describes recombinant viruses derived from this virus and the use of the virus, or its recombinants, as a medicament or vaccine. A method is provided for inducing an immune response in individuals who may be immune-compromised, receiving antiviral therapy, or have a pre-existing immunity to the vaccine virus. In addition, a method is provided for the administration of a therapeutically effective amount of the virus, or its recombinants, in a vaccinia virus prime/vaccinia virus boost innoculation regimen. The present invention relates to a method of virus amplification in primary cells which are cultivated in a serum free medium. Viruses produced by this method are advantageously free of any infectious agents comprised in animal sera.
摘要翻译： 本发明提供一种减毒病毒，其衍生自改良的痘苗安卡拉病毒，其特征在于丧失其在人细胞系中繁殖复制的能力。 它还描述了源自该病毒的重组病毒和病毒或其重组体作为药物或疫苗的用途。 提供了一种方法，用于在可能被免疫损害的个体中诱导免疫应答，接受抗病毒治疗或具有疫苗病毒的预先存在的免疫。 此外，提供了一种用于在痘苗病毒原/痘苗病毒增强接种方案中施用治疗有效量的病毒或其重组体的方法。 本发明涉及在无血清培养基中培养的原代细胞中的病毒扩增方法。 通过该方法产生的病毒有利地不含动物血清中包含的任何传染性物质。
-
公开(公告)号：US08268329B2
公开(公告)日：2012-09-18
申请号：US13053450
申请日：2011-03-22
IPC分类号： A61K39/285
CPC分类号： C07K14/005 , A61K39/12 , A61K39/285 , A61K48/00 , A61K2039/5254 , A61K2039/5256 , A61K2039/53 , A61K2039/545 , C12N7/00 , C12N15/86 , C12N2710/24121 , C12N2710/24143 , C12N2740/16322
摘要： The present invention provides an attenuated virus, which is derived from Modified Vaccinia Ankara virus, wherein the MVA-BN virus, or a derivative thereof, induces at least substantially the same level of immunity in vaccinia virus prime/vaccina virus boost regimes when compared to DNA prime/vaccinia virus boost regimes. It further describes recombinant viruses derived from this virus and the use of the virus, or its recombinants, as a medicament or vaccine. A method is provided for inducing an immune response in individuals who may be immune-compromised, receiving antiviral therapy, or have a pre-existing immunity to the vaccine virus.
摘要翻译： 本发明提供了一种减毒病毒，其来源于改良的痘苗病毒安卡拉病毒，其中MVA-BN病毒或其衍生物在痘苗病毒原/疫苗病毒增强方案中诱导至少基本相同的免疫水平， DNA原核/痘苗病毒增强体系。 它还描述了源自该病毒的重组病毒和病毒或其重组体作为药物或疫苗的用途。 提供了一种方法，用于在可能被免疫损害的个体中诱导免疫应答，接受抗病毒治疗或具有疫苗病毒的预先存在的免疫。
-
公开(公告)号：US07939086B2
公开(公告)日：2011-05-10
申请号：US12471144
申请日：2009-05-22
IPC分类号： A61K39/00 , A61K39/12 , A61K39/295 , A61K39/285 , A61K45/00 , C12N7/00 , C12N7/04 , C12N15/00 , A61K39/165
CPC分类号： C07K14/005 , A61K39/12 , A61K39/285 , A61K48/00 , A61K2039/5254 , A61K2039/5256 , A61K2039/53 , A61K2039/545 , C12N7/00 , C12N15/86 , C12N2710/24121 , C12N2710/24143 , C12N2740/16322
摘要： The present invention provides an attenuated virus, which is derived from Modified Vaccinia Ankara virus, wherein the MVA-BN virus, or a derivative thereof, induces at least substantially the same level of immunity in vaccinia virus prime/vaccina virus boost regimes when compared to DNA prime/vaccinia virus boost regimes. It further describes recombinant viruses derived from this virus and the use of the virus, or its recombinants, as a medicament or vaccine. A method is provided for inducing an immune response in individuals who may be immune-compromised, receiving antiviral therapy, or have a pre-existing immunity to the vaccine virus.
-
公开(公告)号：US20090017536A1
公开(公告)日：2009-01-15
申请号：US12200295
申请日：2008-08-28
申请人： Paul Chaplin , Paul Howley , Christine Meisinger-Henschel , Ingmar Rathe , Eva Felder , Karl Heller
发明人： Paul Chaplin , Paul Howley , Christine Meisinger-Henschel , Ingmar Rathe , Eva Felder , Karl Heller
IPC分类号： C12N5/06
CPC分类号： A61K39/285 , A61K39/12 , A61K48/00 , A61K2039/5254 , A61K2039/5256 , A61K2039/53 , A61K2039/545 , C07K14/005 , C12N7/00 , C12N15/86 , C12N2710/24134 , C12N2710/24143 , C12N2710/24151 , C12N2740/16322
摘要： The present invention provides an attenuated virus, which is derived from Modified Vaccinia Ankara virus and characterized by the loss of its capability to reproductively replicate in human cell lines. It further describes recombinant viruses derived from this virus and the use of the virus, or its recombinants, as a medicament or vaccine. A method is provided for inducing an immune response in individuals who may be immune-compromised, receiving antiviral therapy, or have a pre-existing immunity to the vaccine virus. In addition, a method is provided for the administration of a therapeutically effective amount of the virus, or its recombinants, in a vaccinia virus prime/vaccinia virus boost inoculation regimen. The present invention relates to a method of virus amplification in primary cells which are cultivated in a serum free medium. Viruses produced by this method are advantageously free of any infectious agents comprised in animal sera.
摘要翻译： 本发明提供一种减毒病毒，其衍生自改良的痘苗安卡拉病毒，其特征在于丧失其在人细胞系中繁殖复制的能力。 它还描述了源自该病毒的重组病毒和病毒或其重组体作为药物或疫苗的用途。 提供了一种方法，用于在可能被免疫损害的个体中诱导免疫应答，接受抗病毒治疗或具有疫苗病毒的预先存在的免疫。 此外，提供了一种用于在痘苗病毒原/痘苗病毒加强接种方案中施用治疗有效量的病毒或其重组体的方法。 本发明涉及在无血清培养基中培养的原代细胞中的病毒扩增方法。 通过该方法产生的病毒有利地不含动物血清中包含的任何传染性物质。
-
-
-
-
-
-
-
-
-
搜索结果
74 条记录 (耗时 0.028 秒)
